drugset / Trial / NCT05641493
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
NaSingle-groupOpen-labelTreatment
Summary
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients with BRAF V600 mutation.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2025-03-04
- Completion
- 2026-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX208 | Unknown | 600 mg | Oral |
| Subject | HLX208 | Unknown | 900 mg | Oral |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |